Strategy MSTR · NASDAQ
$136.02 -0.59% (-$0.81)
Summary
37 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 2,276 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 1.5% a year over the last 3 years.
- It missed profit estimates 6 times in the last 8 quarters.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 0.1% a year over 5 years. Over the last 3 years it fell by 1.5% a year. For the next fiscal year analysts expect revenue to grow by 4.9%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $30.4B.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 18
- Hold 8
- Sell 3
Today's price within the analysts' price targets
The average target of $252 is 85% above today's price. 62% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product support 43%
- Subscription services 37%
- Other services 12%
- Product licenses 8.3%
By region
- North America 57%
- E M E A 34%
- Other Regions 8.9%
Product support brings in 43% of revenue.
Segments in detail